Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept

• Conditions: The Injection Burden
• Interventions: Drug: IVA group

• Registration Number: NCT02126904
• Lead Sponsor: Yokohama City University Medical Center

Brief Summary

The investigators compared the time to recurrence after ranibizumab or aflibercept loading in patients with AMD.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-01
• Primary Completion: 2013-10
• Status Verified: 2014-04
• Study First Submitted: 2014-04-27
• Study First Submitted QC: 2014-04-28
• Last Update Submitted: 2014-04-28
• Study First Posted: 2014-04-30
• Last Update Posted: 2014-04-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• They must have had BCVA better than 20/400 and had three consecutive induction treatment of ranibizumab or aflibercept.

Exclusion Criteria

• patients with eye diseases that could potentially influence the visual acuity of the studied eye, such as glaucoma, macular hole, diabetic retinopathy, or rhegmatogenous retinal detachment.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
IVR group	IVA group	-

Primary Outcome Measures

Name	Time	Method
Time to recurrence after induction phase	More than 3 months from baseline	Time frame depends on patients because recurrence time is different.

Trial Locations

Locations (1)

Yokohama City University Medical Center; 🇯🇵 Yokohama, Kanagawa, Japan